Peridot Acquisition Corp. II

We intend to target opportunities and companies that focus on environmentally sound infrastructure, industrial applications and disruptive technologies that eliminate or mitigate GHG emissions and/or enhance resilience to climate change, a thematic that we refer to as “Mitigation and Adaptation.” Rapidly growing societal and political focus on these critical issues has driven considerable corporate, institutional […]

March 9, 2021 Read More

Agile Growth Corp.

Our intention is to capitalize on the ability of our management and board to identify, acquire and operate a business in the technology industry, including pure software and software-enabled businesses such as infrastructure and horizontal and vertical enterprise application software, healthcare IT (“HCIT”), financial technology (“fintech”), robotics/automation, and education technology, as well as potential additional […]

March 8, 2021 Read More

Vector Acquisition Corporation II

(Note: This is a SPAC offering of Class A ordinary shares, NOT units. Most SPAC IPOs are unit offerings.) We intend to capitalize on the ability of our management team and the broader Vector Capital platform to identify, acquire, and operate a business in the technology and technology-enabled services sectors that may provide opportunities for attractive […]

Read More

SVF Investment Corp. 3

We believe that we are now in the early years of a new stage of the information revolution, which will in time be viewed as being as significant a step forward in human history as the Industrial Revolution. The twin impacts of artificial intelligence (“AI”) and the global transition to the interconnection of everyday computing […]

Read More

SVF Investment Corp. 2

Note: This SoftBank Vision Fund-backed SPAC is offering Class A ordinary common shares, NOT units. The company switched its IPO to a stock offering from a unit offering in an S-1/A filing dated March 4, 2021. From the prospectus: “AI (artificial intelligence), mobile communications technology, cloud technologies, robotics, software, consumer Internet and financial technology, as […]

Read More

Colonnade Acquisition Corp. II

We intend to focus on companies with enterprise values ranging from $1 billion to $3 billion. Our management team is led by Joseph Sambuco, chairman, who is also the chairman and CEO of Colonnade Properties, and Remy Trafelet, the president and CEO of Trafelet & Co., a private investment firm that invests across a broad range […]

Read More

Independence Holdings Corp.

We intend to focus on FinTech (financial technology and FinTech services) companies. (Incorporated in the Cayman Islands) Our senior sponsors amd co-chairmen are Steve McLaughlin, the founder, CEO and owner of Financial Technology Partners LP, and Gene Yoon, the founder of Bregal Sagemount,  a tech-focused private investment firm. Mr. McLaughlin is a pioneer in the […]

Read More

Olo, Inc.

Olo provides a leading cloud-based on-demand commerce platform for multi-location restaurant brands. Clients include Five Guys, Wingstop, Shake Shack, Applebee’s, Chili’s and The Cheesecake Factory, Denny’s, Cracker Barrel, Bob Evans Farms, Peets Coffee, Jamba, Milk, sweetgreen, Jimmy John’s Sandwiches, Dairy  Queen and Checkers.  From the prospectus: “Our platform powers restaurant brands’ on-demand commerce operations, enabling […]

Read More

Longboard Pharmaceuticals, Inc.

We are a clinical-stage biopharmaceutical company focused on developing novel transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of […]

Read More

Prometheus Biosciences

We are a biotechnology company pioneering a precision medicine approach to the discovery, development and commercialization of novel therapeutic and companion diagnostic products to treat inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop […]

Read More